Summit Therapeutics Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los ingresos de Summit Therapeutics aumenten en un 85.4% al año.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 28.3% |
| Tasa de crecimiento de los ingresos | 85.4% |
| Rentabilidad financiera futura | -29.4% |
| Cobertura de analistas | Low |
| Última actualización | 18 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?
Nov 08
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Oct 04Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Sep 19Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Sep 09Summit Therapeutics May Have Further Upside From Here
Aug 03Summit Therapeutics Stock: Plunging Despite A Win?
May 31Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
May 06Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
Jan 30We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely
Dec 29Summit Therapeutics slips on plans to terminate study for lead candidate
Oct 04Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Aug 17Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Aug 11Summit to explore additional trial for its bacteria-induced colon infection drug
Jul 14Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation
Apr 29Summit Therapeutics - Disappointing Data But Not An Outright Failure
Dec 23Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator
Jun 22Summit Therapeutics to join Russell 3000 Index
Jun 08Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 48 | N/A | N/A | -286 | 4 |
| 12/31/2025 | N/A | N/A | N/A | -165 | 4 |
| 12/31/2024 | N/A | N/A | N/A | -148 | 4 |
| 9/30/2024 | N/A | -197 | -128 | -113 | N/A |
| 6/30/2024 | N/A | -162 | -98 | -97 | N/A |
| 3/31/2024 | N/A | -116 | -94 | -94 | N/A |
| 12/31/2023 | N/A | -615 | -552 | -77 | N/A |
| 9/30/2023 | N/A | -598 | -527 | -52 | N/A |
| 6/30/2023 | 0 | -598 | -521 | -46 | N/A |
| 3/31/2023 | 0 | -600 | -511 | -36 | N/A |
| 12/31/2022 | 1 | -79 | -42 | -42 | N/A |
| 9/30/2022 | 1 | -87 | -57 | -56 | N/A |
| 6/30/2022 | 2 | -85 | -72 | -71 | N/A |
| 3/31/2022 | 2 | -93 | -72 | -71 | N/A |
| 12/31/2021 | 2 | -89 | -73 | -73 | N/A |
| 9/30/2021 | 2 | -75 | -72 | -71 | N/A |
| 6/30/2021 | 1 | -73 | -65 | -64 | N/A |
| 3/31/2021 | 1 | -64 | -64 | -64 | N/A |
| 12/31/2020 | 1 | -53 | -49 | -48 | N/A |
| 9/30/2020 | 1 | -51 | -49 | -49 | N/A |
| 6/30/2020 | 1 | -40 | -38 | -37 | N/A |
| 3/31/2020 | -5 | -31 | -18 | -18 | N/A |
| 12/31/2019 | 1 | -32 | -23 | -23 | N/A |
| 10/31/2019 | 26 | -28 | -24 | -23 | N/A |
| 7/31/2019 | 24 | -27 | -20 | -19 | N/A |
| 4/30/2019 | 72 | 12 | -24 | -24 | N/A |
| 1/31/2019 | 57 | 11 | -35 | -35 | N/A |
| 10/31/2018 | 70 | 2 | -36 | -36 | N/A |
| 7/31/2018 | 72 | 11 | N/A | -45 | N/A |
| 4/30/2018 | 27 | -29 | N/A | -19 | N/A |
| 1/31/2018 | 20 | -29 | N/A | -21 | N/A |
| 10/31/2017 | 15 | -18 | N/A | -20 | N/A |
| 7/31/2017 | 12 | -23 | N/A | 31 | N/A |
| 4/30/2017 | 5 | -27 | N/A | 14 | N/A |
| 1/31/2017 | 3 | -27 | N/A | 15 | N/A |
| 10/31/2016 | 1 | -29 | N/A | 15 | N/A |
| 7/31/2016 | 1 | -33 | N/A | -26 | N/A |
| 4/30/2016 | 1 | -32 | N/A | -29 | N/A |
| 1/31/2016 | 2 | -29 | N/A | -24 | N/A |
| 10/31/2015 | 2 | -25 | N/A | -23 | N/A |
| 7/31/2015 | 3 | -20 | N/A | -20 | N/A |
| 4/30/2015 | 3 | -19 | N/A | -21 | N/A |
| 1/31/2015 | 3 | -17 | N/A | -17 | N/A |
| 10/31/2014 | 3 | -17 | N/A | -16 | N/A |
| 7/31/2014 | 4 | -17 | N/A | -16 | N/A |
| 4/30/2014 | 4 | -13 | N/A | -11 | N/A |
| 1/31/2014 | 3 | -10 | N/A | -10 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de SMMT es superior a la tasa de ahorro (2.6%).
Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de SMMT crezcan más rápidamente que el mercado US
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de SMMT crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que SMMT no tenga ingresos el año que viene.
Ingresos de alto crecimiento: Se prevé que SMMT no tenga ingresos el año que viene.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: SMMT se prevé que no sea rentable en 3 años.